Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance
Φόρτωση...
Ημερομηνία
Τίτλος Εφημερίδας
Περιοδικό ISSN
Τίτλος τόμου
Εκδότης
Περίληψη
Τύπος
Είδος δημοσίευσης σε συνέδριο
Είδος περιοδικού
peer-reviewed
Είδος εκπαιδευτικού υλικού
Όνομα συνεδρίου
Όνομα περιοδικού
Int J Clin Pract
Όνομα βιβλίου
Σειρά βιβλίου
Έκδοση βιβλίου
Συμπληρωματικός/δευτερεύων τίτλος
Περιγραφή
BACKGROUND: Statin treatment may be associated with adverse effects on glucose metabolism. Whether this is a class effect is not known. In contrast, ezetimibe monotherapy may beneficially affect insulin sensitivity. OBJECTIVE: The aim of this study was to compare the effects of three different regimens of equivalent low-density lipoprotein cholesterol (LDL-C) lowering capacity on glucose metabolism. METHODS: A total of 153 patients (56 men), who had not achieved the LDL-C goal recommended by the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) despite a 3-month dietary and lifestyle intervention, were randomly allocated to receive open-label simvastatin 40 mg or rosuvastatin 10 mg or simvastatin/ezetimibe 10/10 mg for 12 weeks. The primary end point was changes in homeostasis model assessment of insulin resistance (HOMA-IR). Secondary endpoints consisted of changes in fasting insulin levels, fasting plasma glucose (FPG), glycosylated haemoglobin (HbA(1c) ), the HOMA of beta-cell function (HOMA-B) (a marker of basal insulin secretion by pancreatic beta-cells), LDL-C and high sensitivity C reactive protein (hsCRP). RESULTS: At week 12, all three treatment regimens were associated with significant increases in HOMA-IR and fasting insulin levels (p < 0.05 compared with baseline). No significant difference was observed between groups. No change in FPG, HbA(1c) and HOMA-B levels compared with baseline were noted in any of the three treatment groups. Changes in serum lipids and hsCRP were similar across groups. CONCLUSION: To the extent that simvastatin 40 mg, rosuvastatin 10 mg and simvastatin/ezetimibe 10/10 mg are associated with adverse effects on insulin resistance, they appear to be of the same magnitude.
Περιγραφή
Λέξεις-κλειδιά
Aged, Azetidines/administration & dosage/*adverse effects, Blood Glucose/drug effects/metabolism, Body Mass Index, Cholesterol, LDL/metabolism, Drug Combinations, Fasting/blood, Female, Fluorobenzenes/administration & dosage/*adverse effects, Homeostasis/drug effects, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage/*adverse, effects, Hypercholesterolemia/*drug therapy, Insulin Resistance/*physiology, Male, Medication Adherence, Middle Aged, Pyrimidines/administration & dosage/*adverse effects, Simvastatin/administration & dosage/*adverse effects, Sulfonamides/administration & dosage/*adverse effects, Treatment Outcome
Θεματική κατηγορία
Παραπομπή
Σύνδεσμος
http://www.ncbi.nlm.nih.gov/pubmed/21995692
http://onlinelibrary.wiley.com/store/10.1111/j.1742-1241.2011.02779.x/asset/j.1742-1241.2011.02779.x.pdf?v=1&t=h0m94h2p&s=25f39563683e244c29452d6abce9c3daef94ec89
http://onlinelibrary.wiley.com/store/10.1111/j.1742-1241.2011.02779.x/asset/j.1742-1241.2011.02779.x.pdf?v=1&t=h0m94h2p&s=25f39563683e244c29452d6abce9c3daef94ec89
Γλώσσα
en
Εκδίδον τμήμα/τομέας
Όνομα επιβλέποντος
Εξεταστική επιτροπή
Γενική Περιγραφή / Σχόλια
Ίδρυμα και Σχολή/Τμήμα του υποβάλλοντος
Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής